Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): PD-L1 subgroup analysis from HERIZON-GEA-01.

Journal of Clinical Oncology 2026

View at publisher
Authors: Sun Young Rha, Kohei Shitara, Lin Shen, Josep Tabernero, Tianshu Liu, Keun-Wook Lee, Michael Schenker, Niall C. Tebbutt, Jaffer A. Ajani, Norhidayu Salimin, Geoffrey Yuyat Ku, Jong Gwang Kim
+8 more Inmaculada Alés Díaz, Jingdong Zhang, Filippo Pietrantonio, Li-Yuan Bai, Samuel Le Sourd, Ye Chen, Jonathan E. Grim, Elena Elimova
DOI: 10.1200/jco.2026.44.16_suppl.4010
Cited by: 1

Abstract

4010 Background: In HERIZON-GEA-01 (NCT05152147), 1L zanidatamab + CT ± tislelizumab significantly improved progression-free survival (PFS) and, with tislelizumab, yielded a statistically significant overall survival (OS) benefit in HER2+ mGEA. Here we report efficacy in PD-L1 subgroups. Methods: Eligible patients (pts) with previously untreated HER2+ mGEA, irrespective of PD-L1 status, were randomized (1:1:1) to zanidatamab (1800 mg [

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Esophageal Cancer Research and Treatment HER2/EGFR in Cancer Research

Publication details

Journal / source
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Volume
44
Issue
16_suppl
Pages
4010–4010
Publication date
27 May 2026
Language
EN